September 20 - 21, 2019



Las Vegas, NV

CME/CE Credit


Rheumatologists • Internists • Family Physicians • Physician Assistants • Nurse Practitioners • Nurses • Pharmacists


After completing this live activity, participants should be better able to:

  • Review new and emerging ACR/EULAR guidelines for rheumatic disorders.
  • Describe the screening assays for ANA and how to interpret the results.
  • Match specific cutaneous manifestations with the various connective tissue diseases.
  • Distinguish between gout and other crystalline-induced arthropathies and their respective treatments.
  • Differentiate the clinical manifestations of gout, calcium pyrophosphate and basic phosphate induced arthritis.
  • Describe the appropriate use of synovial fluid analysis in the diagnosis of acute arthritis.
  • Identify the role of color duplex sonography in the diagnosis of giant cell arteritis.
  • Describe the current and emerging treatment options for giant cell arteritis.
  • Integrate imaging options to aid in the diagnosis of gout.
  • Recognize evidence-based recommendations for dosing urate-lowering therapies to optimize efficacy in patients with gout.
  • Establish treatment plans for gout that achieve targeted levels of serum uric acid.
  • Prescribe management options for patients with complex medical conditions that complicate the management of their gout.
  • Describe therapeutic options for patients who do not reach target serum urate levels with usual dosing of allopurinol.
  • Discuss the value of dramatic lowering of the serum urate to <1 mg/dL in selected patients with gout.
  • Describe the role of the microbiome in eliciting the immune response.
  • Identify mechanisms by which the microbiome could cause rheumatic disease.
  • Discuss how greater understanding of the relationship between the microbiome and rheumatic diseases could inform future therapies.
  • Describe how myositis-specific autoantibodies define different types and subtypes of inflammatory myopathy.
  • Develop strategies for managing patients with the different types of inflammatory myopathy.
  • Describe current therapeutic approaches to symptomatic osteoarthritis.
  • Determine the relative value of currently popular unconventional approaches to osteoarthritis.
  • Identify important targets of osteoarthritis therapy currently under development.
  • Review the diagnostic evaluation for osteopenia and osteoporosis.
  • Identify how current and emerging agents might fit in the treatment strategy for osteoporosis.
  • Identify the underlying mechanisms responsible for chronic pain.
  • Compare and contrast the safety, efficacy, and mechanisms of various agents available for managing pain in the context of autoimmune disorders.
  • Determine the optimal manner to incorporate non-pharmacological treatment of pain into clinical practice.
  • Demonstrate awareness of current guidelines for management of psoriasis.
  • Outline treatment plans for psoriasis that consider the use of new agents, with new mechanisms, and that include strategies for modifying treatment as needed based on results and patient satisfaction.
  • Create a treatment plan for psoriatic arthritis that incorporates tools for assessing the impact of psoriatic arthritis and that anticipates the potential need to switch or augment therapy.
  • Describe the safety and efficacy of available agents for psoriatic arthritis.
  • Discuss the signs and symptoms suggestive of developing early psoriatic arthritis.
  • Develop a treatment strategy for patients with psoriatic arthritis.
  • Identify the features of a patient who has difficult-to-treat (D2T) RA.
  • Describer the factors that underlie D2T RA.
  • Generate a clinical management plan to address the needs of people with D2T RA.
  • Design effective treatment strategies for the various manifestations of localized and systemic scleroderma.
  • Discuss current understanding of the screening, diagnosis and management of lung disease in scleroderma.
  • Develop a strategy for identifying and managing cutaneous adverse reactions.
  • Summarize the diagnosis and management of different types of statin-related muscle complaints.
  • Summarize current and emerging research on the mechanisms of the pathology of systemic lupus erythematosus and treatment of lupus nephritis.
  • Review data from clinical trials – including failed trials – on candidate therapies that target various pathways involved in systemic lupus erythematosus.
Accreditation and Designation statements


This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of the University of Louisville and Global Academy for Medical Education, LLC. The University of Louisville is accredited by the ACCME to provide continuing education for physicians.

The University of Louisville Office of Continuing Medical Education & Professional Development designates this live activity for a maximum of 13.5 AMA PRA Category 1 CreditsTM. Physicians should only claim credit commensurate with the extent of their participation in the activity.


Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn 13.5 MOC points in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program.

AAFP Credit

Application for CME credit has been filed with the American Academy of Family Physicians. Determination of credit is pending.


Joint Accreditation Statement

 In support of improving patient care, this activity has been planned and implemented by the Postgraduate Institute for Medicine and Global Academy for Medical Education. Postgraduate Institute for Medicine is jointly accredited by the American Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Continuing Pharmacy Education

Postgraduate Institute for Medicine designates this continuing education activity for 13.5 contact hours (1.35 CEUs) of the Accreditation Council for Pharmacy Education.  Type of Activity: Application

Continuing Nursing Education

The maximum number of hours awarded for this Continuing Nursing Education activity is 13.5 contact hours.  Pharmacotherapy contact hours for Advanced Practice Nurses will be designated on certificates.


Follow Us

Jointly Provided By

In Association With